Editing Metastatic Kidney Cancer (section)

== Answers ==

# What are the IMDC criteria and the risk groups?
#* '''K-PINCH'''
## KPS < 80
## Platelets (>upper limit of normal)
## Interval from diagnosis to treatment <1 year
## Neutrophils (>upper limit of normal)
## Calcium (>10g/dL)
## Hemoglobin (<lower limit of normal)
#* Favourable-risk: 0 factors
#* Intermediate-risk: 1-2 factors
#* Poor-risk: ≥3 factors
# Describe the CARMENA and SURTIME trials?
#* CARMENA: RCT of approximately 400 patients with intermediate/poor-risk mcRCC randomized to upfront sunitnib vs. upfront CN followed by sunitnib. Primary outcome OS. Upfront sunitnib was non-inferior to upfront CN + sunitnib
#* SURTIME: RCT of approximatley 100 patients with mcRCC randomized to upfront sunitnib followed by CN vs. upfront CN followed by sunitnib. Primary outcome was progression. No difference in progression.
# As per the 2019 CUA Consensus Statement on CN, what are the criteria for offering upfront CN?
## Good performance status (Eastern Cooperative Oncology Group [ECOG] ≤1 or Karnofsky performance status (KPS) ≥80%)
## Resectable primary tumour
## Limited burden of metastatic disease
## Minimal symptoms related to metastases
## No active CNS metastases
# What does nivolumab target? Ipilimumab?
#* Nivolumab: PD-1
#* Ipilimumab: CTLA-1
# List VEGF inhibitors used in RCC.
## Sunitnib
## Sorafenib
## Bevacizumab
## Pazopanib
## Axitnib
# List mTOR inhibitors used in RCC.
## Everolimus
## Temsirolimus
# What is the preferred first-line systemic treatment in metastatic ccRCC?
#* Favourable-risk: axitnib + pembrolizumab
#* Intermediate/poor-risk: axitnib + pembrolizumab or nivolumab + ipilimumab